Daniel J. Rader, MD is the Cooper-McClure Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. He serves as the Chair of Genetics and Chief of the Division of Translational Medicine and Human Genetics in the Department of Medicine and is Associate Director of Penn’s Institute for Translational Medicine and Therapeutics at Penn. Dr. Rader also serves as Director of Translational Science for the Penn’s Cardiovascular Institute.
Dr. Rader’s research focuses on genetic and pharmacologic regulation of lipoprotein metabolism and atherosclerosis, and he directs a translational research program focusing on human genetics of lipid disorders and atherosclerosis and novel approaches to treatment of dyslipidemia and regression of atherosclerosis. He led the scientific and clinical development of a first-in-class inhibitor of microsomal transfer protein for the treatment of severe hypercholesterolemia which is now on the market. He has a particular interest in HDL metabolism and function, and novel approaches to targeting HDL metabolism and reverse cholesterol transport in the treatment, prevention, and regression of atherosclerosis. He has been a leader in the translation of novel findings from human genetics into new biological understanding of mechanism in the area of lipoprotein metabolism and atherosclerosis.
Dr Rader trained in internal medicine at Yale-New Haven Hospital and in lipid research at the National Institutes of Health. He has been on the Penn faculty since 1994. Dr. Rader is a member of the American Society of Clinical Investigation, the Association of American Physicians, and the Institute of Medicine. He is a recipient of several awards including the Clinical Research Award from the American Heart Association in 2012. Dr. Rader is a frequently invited speaker nationally and internationally on his basic and translational research in lipoprotein metabolism and atherosclerosis.
« Go Back